Stereotaxis (STXS)
(Delayed Data from AMEX)
$2.04 USD
+0.06 (3.03%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $2.02 -0.02 (-0.98%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth D Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$2.04 USD
+0.06 (3.03%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $2.02 -0.02 (-0.98%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth D Momentum F VGM
Zacks News
Stereotaxis (STXS) Achieves CE Mark in Europe for GenesisX
by Zacks Equity Research
Stereotaxis (STXS) gets a CE mark in Europe for its GenesisX robotic system. Following this, the company also submits a 501(k) application for FDA clearance.
Stereotaxis (STXS) Receives European Approval for GenesisX
by Zacks Equity Research
Stereotaxis (STXS) gains CE mark for GenesisX and plans to launch the system in 2025.
Stereotaxis Inc. (STXS) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Stereotaxis (STXS) delivered earnings and revenue surprises of -75% and 21.02%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
AxoGen (AXGN) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
AxoGen (AXGN) delivered earnings and revenue surprises of 200% and 10.74%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Masimo (MASI) Tops Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Masimo (MASI) delivered earnings and revenue surprises of 11.69% and 0.24%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Si-Bone (SIBN) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Si-Bone (SIBN) delivered earnings and revenue surprises of 15.38% and 2.62%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Stereotaxis (STXS) Gets CE Recertification for Approved Products
by Zacks Equity Research
Stereotaxis' (STXS) receives updated EU Quality Management System Certificate, which demonstrates compliance with MDR.
Stereotaxis' (STXS) RMN System to Aid in Treating Arrhythmias
by Zacks Equity Research
Stereotaxis (STXS) announces the completion of treatment of first heart rhythm patients with its Genesis Robotic Magnetic Navigation system in Southern Italy.
Stereotaxis (STXS) Inks Deal to Buy Access Point Technologies
by Zacks Equity Research
Stereotaxis' (STXS) deal to acquire electrophysiology catheter developer, Access Point Technologies, is likely to strengthen its position within the catheter market.
Stereotaxis (STXS) Seeks Clearance for MAGiC Catheter
by Zacks Equity Research
Stereotaxis (STXS) announces the regulatory submissions of its MAGiC catheter in Europe and the United States, which are intended for use in minimally invasive cardiac ablation treatments.
Alphatec (ATEC) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Alphatec (ATEC) delivered earnings and revenue surprises of -32.14% and 0.27%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Penumbra (PEN) Q4 Earnings Beat Estimates
by Zacks Equity Research
Penumbra (PEN) delivered earnings and revenue surprises of 7.04% and 1%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
AxoGen (AXGN) Moves 6.8% Higher: Will This Strength Last?
by Zacks Equity Research
AxoGen (AXGN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Stereotaxis Inc. (STXS) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Stereotaxis Inc. (STXS) delivered earnings and revenue surprises of -16.67% and 9.15%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
KORU Medical Systems Inc. (KRMD) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
KORU Medical Systems Inc. (KRMD) delivered earnings and revenue surprises of 0% and 0.09%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Steris (STE) Q1 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Steris (STE) delivered earnings and revenue surprises of 7.53% and 7.75%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Down -32.11% in 4 Weeks, Here's Why You Should You Buy the Dip in Stereotaxis Inc. (STXS)
by Zacks Equity Research
Stereotaxis Inc. (STXS) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Stereotaxis Inc. (STXS) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Stereotaxis Inc. (STXS) delivered earnings and revenue surprises of -40% and 0.74%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Stereotaxis Inc. (STXS) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
Stereotaxis Inc. (STXS) delivered earnings and revenue surprises of 0% and 23.95%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Tactile Systems Technology (TCMD) Q4 Earnings and Revenues Top Estimates
by Zacks Equity Research
Tactile Systems Technology (TCMD) delivered earnings and revenue surprises of 107.14% and 4.82%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Stereotaxis Inc. (STXS) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Stereotaxis Inc. (STXS) delivered earnings and revenue surprises of -16.67% and 2.46%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Delcath Systems, Inc. (DCTH) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Delcath Systems, Inc. (DCTH) delivered earnings and revenue surprises of 12.38% and 10.49%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Thermo Fisher Scientific (TMO) Beats Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Thermo Fisher (TMO) delivered earnings and revenue surprises of 6.28% and 8.30%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Stereotaxis Inc. (STXS) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Stereotaxis Inc. (STXS) delivered earnings and revenue surprises of -16.67% and 19.05%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Orthofix (OFIX) Beats Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Orthofix (OFIX) delivered earnings and revenue surprises of 14.29% and 0.57%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?